D

Summit Therapeutics Inc. SMMT

$10.50 -$0.17-1.59% NASDAQ
Recommendation
Dividend Power Score
Day's Range
$10.14$11.39
Latest Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
My Lists My Alerts
Access our Premium Ratings
Get Access

SMMT Rating

Reward
Risk

SMMT Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

SMMT Company Overview

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for oncology and infectious diseases, with its current strategic emphasis centered on cancer immunotherapy. The company operates primarily in the biotechnology and pharmaceutical industries and is publicly traded on Nasdaq under the ticker SMMT. Summit’s core value proposition is built around advancing differentiated therapeutic candidates through clinical development, particularly bispecific antibody therapies intended to improve outcomes for patients with difficult-to-treat cancers. Its principal revenue and valuation drivers are tied to clinical-stage drug development milestones, licensing arrangements, and potential future commercialization opportunities rather than current large-scale product sales.

The company was originally founded in the United Kingdom and historically concentrated on antibiotics targeting multidrug-resistant infections, including programs for Clostridioides difficile. Over time, Summit evolved into an oncology-focused organization through strategic restructuring and licensing activity. A major turning point came with the licensing and development partnership surrounding ivonescimab, a bispecific antibody targeting PD-1 and VEGF pathways, originally developed by Akeso, Inc. Public filings and investor materials indicate that Summit repositioned itself to pursue late-stage oncology development opportunities with potential global commercial relevance, particularly in non-small cell lung cancer and related solid tumor indications.

Data compiled by narrative technology. May contain errors.
Sector

SMMT Income Statement

Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

SMMT Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

SMMT Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

SMMT Price History

Loading...
52-Week Range0% of range
Current
$10.50
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return

SMMT Valuation

Market Cap
Market Cap Rank
#2,640
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)

SMMT Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--

SMMT Corporate Info

Phone Number
305 203 2034
Address
601 Brickell Key Drive
Suite 1000
Miami, FL 33131
Country
Year Founded

SMMT Filings

Filing Date
Wednesday, November 4, 2026
Period Date
Wednesday, September 30, 2026
Next Filing
Week of Feb 22 and 26 (est)

SMMT Headlines

11/16/2026 - Pharmaceutical Business Review
11/16/2026 - TipRanks: TheFly
11/16/2026 - Zacks Investment Research